Recombinant Human NT-pro-BNP

來源: 發(fā)布時(shí)間:2024-04-14

SARS-CoV-2,whichcausestheglobalpandemiccoronavirusdisease2019(Covid-19),belongstoafamilyofvirusesknownascoronaviruses.TheSARS-CoV-2Sproteinisaglycoproteinthatmediatesmembranefusionandviralentry.TheRBDofSARS-CoV-2bindsametallopeptidase,angiotensin-convertingenzyme2(ACE-2).SeveralemergingSARS-CoV-2genomeshavebeenidentifiedincludingtheOmicron,orB.1.1.529,variant.FirstidentifiedinNovember2021inSouthAfrica,theOmicronvariantquicklybecamethepredominantSARS-CoV-2variantandisconsideredavariantofconcern(VOC).TheOmicronvariantcontains15mutationsinRBDdomainthatpotentiallyaffectviralfitnessandtransmissibility.ThemajorityofthemutationsareinvolvedinACE-2bindingandOmicronbindsACE-2withgreateraffinity,potentiallyexplainingitsincreasedtransmissibility.Severalofthesemutationsarealsoidentifiedinfacilitatingimmuneescapeandreducingneutralizationactivitytoseveralmonoclonalantibodies.重組腸激酶(rEK)是一種高純度的重組牛腸激酶輕鏈片段,氨基酸序列與牛腸激酶輕鏈一致,有著酶切位點(diǎn)。Recombinant Human NT-pro-BNP

Recombinant Human NT-pro-BNP,標(biāo)準(zhǔn)物質(zhì)

Recombinant Biotinylated Cynomolgus Siglec-10 Protein,His-Avi Tag性能參數(shù)分子別名(Synonyms)SLG2;SIGLEC10;MGC126774;PRO940表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)BiotinylatedCynomolgusSiglec-10ProteinisexpressedfromHEK293withHistagandAvitagattheC-terminus.ItcontainsThr17-Asn552.[Accession|A0A2K5WBX8]分子量大小(MolecularWeight)TheproteinhasapredictedMWof61.71kDa.Duetoglycosylation,theproteinmigratesto72-82kDabasedonSDS-PAGEresult.(Endotoxin)Lessthan1EUperμgbytheLALmethod.純度(Purity)>95%asdeterminedbySDS-PAGE制劑(Formulation)Suppliedas0.22μmfilteredsolutionin25mMMES,150mMNaCl,0.5MArginine(pH5.0).儲(chǔ)存條件Theproductshouldbestoredat-85~-65℃for1yearfromdateofreceipt.Recommendtoaliquottheproteinintosmallerquantitieswhenfirstusedandavoidrepeatedfreeze-thawcycles.Recombinant Human BMP-7 Protein甲磺酸達(dá)比加群酯是一種抗凝藥,通過競爭結(jié)合凝血酶的纖維蛋白特異結(jié)合位點(diǎn),從而抑制血栓的形成。

Recombinant Human NT-pro-BNP,標(biāo)準(zhǔn)物質(zhì)

Recombinant Biotinylated Human HBV (HLA-A*02:01) Protein,His-Avi Tag性能參數(shù)表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)RecombinantBiotinylatedHumanHBV(HLA-A*02:01)ProteinisexpressedfromHEK293withHistagandAvitagattheC-terminalItcontainsGly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)andFLLTRILTIpeptide.[Accession|A0A140T913(HLA-A*02:01)&P61769(B2M)&FLLTRILTIpeptide]分子量大小(MolecularWeight)TheproteinhasapredictedMWof50.5kDa.Duetoglycosylation,theproteinmigratesto52-62kDabasedonTris-BisPAGEresult.(Endotoxin)Lessthan1EUperμgbytheLALmethod.純度(Purity)>95%asdeterminedby>95%asdeterminedbyHPLC制劑(Formulation)Lyophilizedfrom0.22μmfilteredsolutioninPBS(pH7.4).Normally8%trehaloseisaddedasprotectantbeforelyophilization.重構(gòu)方法(Reconstitution)Centrifugetubesbeforeopening.Reconstitutingtoaconcentrationmorethan100μg/mlisrecommended.Dissolvethelyophilizedproteinindistilledwater.

糖苷酶 F (PNGase F)酶活定義(UnitDefinition)1個(gè)酶活力單位指在10μL的反應(yīng)體系中,37℃條件下1小時(shí)從10μg變性RNaseB中除去超過95%的碳水化合物所需要的酶量。儲(chǔ)存條件-25~-15℃保存,有效期1年。使用方法1、變性條件下蛋白質(zhì)去糖基化:1)在水中加入1μLBuffer1和目標(biāo)糖蛋白(1-20μg),至終體積10μL;2)100℃溫度下煮沸10min使其變性,冰上冷卻,離心10秒;加入2μL的Buffer2、2μL的10%NP-40、6μL去離子水,總反應(yīng)體積20μL;加入1-2μL的PNGase,輕輕混勻。在37℃孵育1-3h。2、非變性條件下蛋白質(zhì)去糖基化:1)在水中加入2μL的Buffer2和目標(biāo)糖蛋白(1-20μg)至體積為20μL。2)加入2~5μL的PNGaseF,輕輕混勻。3)37°C孵育4-24h。注意:在變性條件下大多數(shù)底物能夠更好的去糖基化,在非變性條件下可能需要增加PNGaseF的量和延長孵育時(shí)間。注意事項(xiàng)1.PNGaseF建議搭配我司提供的配套緩沖液使用,按我司說明書建議的操作量配套緩沖液足夠。如您由于使用體系造成配套緩沖液不足,可咨詢當(dāng)?shù)劁N售進(jìn)行購買IdeS Protease全稱免疫球蛋白G降解酶是由人類致病菌釀膿鏈球菌產(chǎn)生并分泌至胞外的一種半胱氨酸水解酶。

Recombinant Human NT-pro-BNP,標(biāo)準(zhǔn)物質(zhì)

Recombinant Biotinylated Human HLA-A*02:01&B2M&MAGE-A4 or MAGE-A8 (KVLEHVVRV) Monomer Protein,His-Avi Tag性能參數(shù)分子別名(Synonyms)MAGE-A4orMAGE-A8;MAGE-A4;MAGE-A8;表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)BiotinylatedHumanHLA-A*02:01&B2M&MAGE-A4orMAGE-A8(KVLEHVVRV)MonomerProteinisexpressedfromHEK293withHistagandAvitagattheC-Terminus.ItcontainsGly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)andKVLEHVVRVpeptide.[Accession|A0A140T913(HLA-A*02:01)&P61769(B2M)&KVLEHVVRV]分子量大?。∕olecularWeight)TheproteinhasapredictedMWof50.50kDa.Duetoglycosylation,theproteinmigratesto52-62kDabasedonSDS-PAGEresult.(Endotoxin)Lessthan1EUperμgbytheLALmethod.純度(Purity)>95%asdeterminedbySDS-PAGEandHPLC.制劑(Formulation)Suppliedas0.22μmfilteredsolutioninPBS(pH7.4).儲(chǔ)存條件Theproductshouldbestoredat-85~-65℃for1yearfromdateofreceipt.在分子生物學(xué)、生物化學(xué)或生物工程制藥研究中也常作為工具酶用于重組融合蛋白的特異性斷裂。Recombinant Mouse FGF-9

OSM與白血病抑制因子(LIF)密切相關(guān),實(shí)際上,除了其在人類中的特定受體外,它實(shí)際上還使用了LIF受體。Recombinant Human NT-pro-BNP

Angiotensin I Converting Enzyme (ACE-2), also called ACEH (ACE homologue), is a dimeric, zinc-dependent metalloprotease of the ACE family that also includes somatic and germinal ACE. ACE-2 mRNA is found at high levels in heart, testis, and kidney and at lower levels in a wide variety of tissues. ACE-2 is the SARS-CoV and SARS-CoV2 Spike protein receptor in vivo, functions catalytically as a carboxypeptidase to cleave several substrates including angiotensins I and II, and acts as a partner for B0AT1-family amino acid transporters. Through these functions, ACE-2 has been shown to be involved in several diseases including SARS, COVID19, acute lung injury, heart disease, liver and lung fibrosis, inflammatory lung disease, and cardiopulmonary disease . Full length ACE-2 protein includes an extracellular region composed of a single N-terminal peptidase domain and C-terminal collectrin-like domain (CLD), a transmembrane domain, and a short cytoplasmic tail. The N-terminal peptidase region is required for binding to SARS-CoV and SARS-CoV2 spike proteins, while the CLD contains a region that promotes dimerization and association with amino acid transporters.Recombinant Human NT-pro-BNP

浦斯瑞(上海)生物醫(yī)藥有限公司是一家有著雄厚實(shí)力背景、信譽(yù)可靠、勵(lì)精圖治、展望未來、有夢想有目標(biāo),有組織有體系的公司,堅(jiān)持于帶領(lǐng)員工在未來的道路上大放光明,攜手共畫藍(lán)圖,在江蘇省等地區(qū)的化工行業(yè)中積累了大批忠誠的客戶粉絲源,也收獲了良好的用戶口碑,為公司的發(fā)展奠定的良好的行業(yè)基礎(chǔ),也希望未來公司能成為*****,努力為行業(yè)領(lǐng)域的發(fā)展奉獻(xiàn)出自己的一份力量,我們相信精益求精的工作態(tài)度和不斷的完善創(chuàng)新理念以及自強(qiáng)不息,斗志昂揚(yáng)的的企業(yè)精神將**浦斯瑞(上海)生物醫(yī)藥供應(yīng)和您一起攜手步入輝煌,共創(chuàng)佳績,一直以來,公司貫徹執(zhí)行科學(xué)管理、創(chuàng)新發(fā)展、誠實(shí)守信的方針,員工精誠努力,協(xié)同奮取,以品質(zhì)、服務(wù)來贏得市場,我們一直在路上!